Background {#Sec1}
==========

Norovirus (NoV) is a common cause of acute gastroenteritis (AGE) worldwide. NoVs are members of the *Caliciviridae* family and are divided into six genogroups, of which genogroups I and II (GI and GII) are responsible for the majority of human disease \[[@CR1], [@CR2]\]. Each genogroup can be further distinguished into genotypes, with GI and GII comprised of at least 9 and 22 genotypes, respectively \[[@CR2]\]. Most human NoV infections are caused by GII strains, and a single genotype, GII.4, is responsible for approximately 55--85% of clinical cases worldwide \[[@CR2]\].

NoV is the most common cause of acute gastroenteritis in outbreak settings \[[@CR3]\]. However, NoV is also a leading cause of AGE among children in the community. Since the introduction of rotavirus vaccines, NoV has replaced rotavirus as the leading cause of medically attended AGE in children \< 5 years of age in the United States \[[@CR4], [@CR5]\]. However, the burden of norovirus-associated diarrheal infections in the pre- and post-rotavirus vaccination era has not been fully characterized in other regions, including southern Africa. We aimed to evaluate the prevalence, clinical features, and molecular epidemiology of NoV infections in children \< 5 years of age in Zambia, a country that implemented infant rotavirus vaccination in 2013, using data from a health facility-based surveillance study.

Methods {#Sec2}
=======

Study setting {#Sec3}
-------------

The study was conducted in six health facilities throughout the Lusaka Province of Zambia. Three facilities were in Lusaka District, the most densely populated urban district in Zambia and three additional facilities were located in each of the three remaining districts, Kafue, Chongwe and Luangwa, which contain a lower density, more rural population. In January 2012 the Zambian Government, in partnership with the Centre for Infectious Disease Research in Zambia (CIDRZ) and Absolute Return for Kids (Ark, a United Kingdom-based children's charity), initiated a 2-year, pilot introduction of the Rotarix® live, oral rotavirus vaccine in public health facilities in Lusaka Province \[[@CR6], [@CR7]\]. Following this successful pilot, the vaccine was nationally implemented into the Expanded Programme on Immunisations (EPI) in November 2013. Facilities that met specific criteria were purposefully selected as study sites, including (i) sufficient numbers of patients under 5 years, (ii) space to support study activities, (iii) and participation in the pilot vaccine roll-out.

Study design {#Sec4}
------------

From July 2012 to October 2013, active health facility-based surveillance was conducted among the six sentinel health facilities to identify and enroll children less than 5 years of age with diarrheal illnesses. Children were considered eligible if they met the following criteria: age 0--59 months; admitted to the inpatient department (IPD) or under care in the outpatient department (OPD) at the time of screening; and verbal confirmation by the caregiver that the child passed three or more abnormally loose stools in the past 24 h. Eligibility criteria also including having signs of potentially severe diarrhea by confirmation of at least one of the following symptoms assessed through physical examination by the study nurse or verbal confirmation by the caregiver: sunken eyes, loss of normal skin turgor, intravenous rehydration prescribed/administered, blood in stool, and hospitalization for diarrhea or dysentery. Inclusion criteria also included presence of a caregiver who could provide written informed consent and who was willing to have study procedures carried out on the eligible child. Subjects who had previously participated in the study within the last 30 days were excluded.

After providing written informed consent, caregivers of participants were interviewed at enrollment to collect detailed information regarding individual and household demographics, symptoms associated with the child's present illness, and the child's health background. The child's vaccination history and growth trajectory were also recorded from the child health record, when available, or by verbal report by caregiver when not. If the child was admitted to the health facility, time-to-discharge and other features of illness were collected. A home visit was also conducted 30 days after enrollment or discharge from the facility to determine the child's vital status.

Stool sample collection and handling {#Sec5}
------------------------------------

Study staff asked the child's caregiver to be notified when the child indicated a need to use the toilet or after the child had produced stool in the diaper. Approximately 10--15 mL of bulk stool was collected from each child at enrollment. Stool specimens were collected in sterile specimen containers, refrigerated immediately after collection, and transported from the study sites to the CIDRZ laboratory in Lusaka.

Laboratory procedures {#Sec6}
---------------------

All stool samples collected were initially screened for rotavirus antigen by enzyme immunoassay (EIA) using a monoclonal antibody solid phase sandwich as part of a larger assessment of rotavirus vaccine effectiveness \[[@CR8]\]. The Meridian Rotaclone EIA kit for the detection of rotavirus antigen in fecal samples (CAT No. 696004) was used for the analysis.

Norovirus RNA isolation and detection {#Sec7}
-------------------------------------

A convenience sample of available stool specimens was processed to undergo norovirus testing by reverse-transcriptase polymerase chain reaction (RT-PCR). RNA was extracted from 140 μL of fecal suspension using the QIAampViral RNA Mini Kit, (Qiagen, Hieden, Germany). Purified RNA aliquots were stored at −80 C. One step RT-PCR was performed on the stored samples using the JV12i/JV13y primers targeting the ORF1 region, which encodes the RNA-dependent RNA-polymerase gene \[[@CR9]\]. The final volume for each reaction was 25 μL. Each reaction contained 5.0 μL of 5x one step RT-PCR buffer; 1.0 μL of 40 μM dNTPs; 0.5 μL of each primer for (20 μM each); 1 μL of One step RT-PCR Enzyme mix (5 U/μL), 5 μL of sample RNA, and 11 μL of nuclease-free water. The amplification conditions were set as follows: Reverse transcription 42 °C for 30 min, followed by 94 °C for 5 min, then 40 cycles of 94 °C for 30 s, 50 °C for 30 s, 72 °C for 30 s, and an extension step at 72 °C for 10 min. All RT-PCR products were analyzed by 1.5% agarose gel electrophoresis.

DNA sequencing and genotyping {#Sec8}
-----------------------------

All positive RT-PCR products were purified using GeneJET PCR Kit (Thermo Scientific) and sequenced with BigDye Terminator v3.1 cycle sequencing kit using an ABI 3130 XL Genetic analyzer (Applied Biosystems, Foster City, CA). Nucleotide sequences were edited with Sequencer Version 5.0. The partial RNA-dependent RNA-polymerase genotypes of sequenced isolates were determined using the Norovirus Genotyping Tool Version 1.0 (National Institute for Public Health and the Environment; Bilthoven, The Netherlands). Phylogenetic relationships of the norovirus were analyzed by aligning sequences from the GenBank database using clustalw software. Phylogenetic trees of nucleotide sequences of the partial RNA-dependent RNA polymerase region of GI or GII isolates were constructed by the neighbor joining method \[[@CR10]\] using MEGA version 5.0 software \[[@CR11]\] and validated by 1000 bootstrap replicates \[[@CR12]\].

Human subjects protection {#Sec9}
-------------------------

The study was approved by research ethics authorities at the Zambian Ministry of Health, the University of Zambia, the University of Alabama at Birmingham, and the University of North Carolina at Chapel Hill. Caregivers of participants provided written informed consent prior to initiation of study procedures.

Statistical analysis {#Sec10}
--------------------

The distribution of genogroups among the norovirus detections sequenced and the seasonality of norovirus detections were described. To compare the clinical features of AGE among norovirus-positive versus norovirus-negative episodes of diarrheal illness, Chi-squared tests and t-tests were utilized for categorical or continuous outcome variables, respectively. Severity scores were calculated post-hoc for each diarrheal illness for which clinical data were available using the 20-point Modified Vesikari score \[[@CR13]--[@CR15]\] and compared among norovirus genogroup and according to viral detection.

Results {#Sec11}
=======

Norovirus prevalence and distribution of genogroups and genotypes {#Sec12}
-----------------------------------------------------------------

A total of 1506 subjects were enrolled in the primary study and provided stool specimens. Rotavirus positivity among these was 41.2% (621/1506). From 1506 stool specimens collected during the study, a convenience sample of 454 (30%) specimens was selected for norovirus testing. Overall, 52/454 (11.5%) of these specimens were positive for norovirus by RT-PCR (Fig. [1](#Fig1){ref-type="fig"}). Of 52 norovirus-positive samples, 43 (82.7%) were successfully sequenced for genogroup characterization. The majority of these (31/43; 72.1%) were GII, while 12/43 (27.9%) were GI.Fig. 1Consort diagram

Genotype determination was not possible in 7/43 samples due to short sequences not supported by MEGA V.5. In the 36 strains genotyped, there were 9 GI samples and 27 GII samples. Of 9 GI strains successfully genotyped, strains clustered as follows: 6 GI.P7, 2 GI.P2, and 1 GI.P5 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A). Of 27 GII strains successfully genotyped, strains clustered as follows: 19 GII.P4, 4 GII.Pe and 4 GII.P2 (Additional file [1](#MOESM1){ref-type="media"}: Figure S1B).

Clinical features of norovirus-positive compared to norovirus-negative diarrheal illnesses {#Sec13}
------------------------------------------------------------------------------------------

Detailed clinical and sociodemographic data were available for 289/454 (63.7%) samples, including 23 of the 52 (44.2%) in which norovirus was detected (Table [1](#Tab1){ref-type="table"}). The mean duration of diarrhea was 2.9 days in these 23 norovirus-positive diarrheal illnesses; no subjects reported bloody diarrhea. Abdominal pain, fever, and vomiting were the most common features present during norovirus infections, and occurred in 15/23 (68.1%), 10/23 (45.4%), and 9/23 (42.9%) norovirus-positive episodes, respectively. Rotavirus was co-detected in 6/23 (26%) episodes of norovirus-positive diarrheal illness; two of these subjects had received one rotavirus vaccine dose, but none had received two rotavirus vaccine doses. NoV detections occurred throughout the year, with no discernible seasonal pattern (Fig. [2](#Fig2){ref-type="fig"}). Ten of 23 (43%) subjects with norovirus infection and clinical data available had received at least one rotavirus vaccine dose. In the subjects in whom all data were available to calculate a Modified Vesikari Score, most (16/19; 84.2%) illnesses were characterized as mild, and the remainder (3/19; 15.8%) were characterized as moderate. Three of 21 (14.3%) children with norovirus-positive diarrheal illness were admitted to the health care facility. None of these children were also rotavirus-positive; length of stay for each admitted child was 2 days.Table 1Sociodemographic and clinical features of norovirus-positive compared to norovirus-negative diarrheal illness episodes in young Zambian childrenNorovirus positive (*n* = 23)Norovirus negative (*n* = 266)*p*Sociodemographic and background characteristics Sex0.240  Female14/22 (63.6)127/257 (49.4)  Male8/22 (36.3)130/257 (50.6) Age0.797   \< 1 month0 (0.0)3/266 (1.1)  1--6 months2/23 (8.7)31/266 (11.7)  6--12 months10/23 (43.5)106/266 (39.8)  12--24 months9/23 (39.1)83/266 (31.2)   \> 24 months2/23 (8.7)43/266 (16.2) Number of siblings0.867  08/21 (38.1)69/210 (32.9)  14/21 (19.1)53/210 (25.2)  24/21 (19.1)48/210 (22.9)  32/21 (9.5)17/210 (8.1)   ≥ 43/21 (14.3)23/210 (11.0) Household electricity15/23 (65.2)164/258 (63.6)0.875 Household drinking water source0.793  Communal tap12/19 (63.1)110/244 (45.1)  Piped to yard3/19 (15.8)39/244 (16.0)  Piped into dwelling2/19 (10.5)36/244 (14.8)  Protected public well1/19 (5.3)21/244 (8.6)  River/stream0/19 (0.0)14/244 (5.7)  Other1/19 (5.3)24/244 (9.8) Household livestock3/23 (13.0)28/251 (11.2)0.784 Toilet facility**0.031**  Flush/pour flush to piped sewer1/20 (5.0)41/225 (18.2)  Flush/pour flush to septic tank3/20 (15.0)42/225 (18.7)  Flush/pour flush to pit latrine3/20 (15.0)3/225 (1.3)  Improved ventilated pit latrine1/20 (5.0)16/225 (7.1)  Pit latrine with slab10/20 (50.0)78/225 (34.7)  Open pit latrine without slab2/20 (10.0)44/225 (19.6)  Hanging toilet/hanging latrine0/20 (0.0)1/225 (0.4) Child ever diagnosed with HIV/AIDS0/18 (0.0)1/201 (0.5)1.000 Number of rotavirus vaccines received  0 doses or unknown13/23 (56.5)171/266 (64.3)  At least 1 dose10/23 (43.4)95/266 (35.7)0.458  2 doses8/23 (34.8)79/266 (30.0)0.610Clinical features at presentation Severity score by category0.766   ≤ 10 (mild)16/19 (84.2)156/183 (85.3)  11--14 (moderate)3/19 (15.8)26/183 (14.2)   ≥ 15 (severe)0/19 (0.0)1/183 (0.6) Degree of dehydration on admission0.319  None2/23 (8.7)57/259 (22.0)  Mild7/23 (30.4)55/259 (21.2)  Moderate14/23 (60.9)136/259 (52.5)  Severe0/23 (0.0)11/259 (4.3) Duration of diarrhea, days0.505  1--421/22 (95.5)203/221 (91.9)  51/22 (4.5)6/221 (2.7)   ≥ 60/22 (0.0)12/221 (5.4) Max stools/day0.444  1--314/22 (63.6)112/217 (51.6)  4--58/22 (36.4)90/217 (41.5)   ≥ 60/22 (0.0)15/217 (6.9) Blood in stool0/22 (0.0)8/216 (3.7)1.000 Vomiting9/21 (42.9)83/221 (37.1)0.603 Duration of vomiting, days0.593  012/22 (54.6)139/221 (62.9)  11/22 (4.6)9/221 (4.1)  25/22 (22.7)49/221 (22.2)   ≥ 34/22 (18.2)24/221 (10.9) Maximum vomiting episodes/day0.502  012/22 (54.6)139/218 (63.8)  10/22 (0.0)5/218 (2.3)  2--410/22 (45.5)65/218 (29.8)   ≥ 50/22 (0.0)9/218 (4.1) Abdominal pain15/22 (68.2)137/205 (66.8)0.898 Caregiver-reported fever10/22 (45.5)97/217 (44.7)0.946 Maximal recorded temperature, °C0.877   \< 37.015/22 (68.2)172/245 (70.2)  37.1--38.47/22 (31.8)60/245 (24.5)  38.5--38.90/22 (0.0)6/245 (2.5)   ≥ 39.00/22 (0.0)7/245 (2.9) Duration of fever2.4 (1.2)2.6 (1.3)0.605 Decreased energy/malaise13/21 (61.9)147/217 (67.7)0.586 Excessive crying14/22 (63.6)96/218 (44.0)0.079 Admitted to hospital3/21 (14.3)32/223 (14.4)1.000 Rotavirus positive6/23 (26.1)104/263 (39.5)0.20330 day follow-up Status of child1.000  Fully recovered10/10 (100.0)120/133 (90.20)  Partially recovered0/10 (0.0)6/133 (4.5)  Worsening0/10 (0.0)1/133 (0.8)  Recovered but became sick again0/10 (0.0)6/133 (4.5)Bold text indicates statistical significance (*p* \< 0.05) Fig. 2Calendar month of collection and norovirus detection among samples collected from young Zambian children with diarrheal illness

The types of household toilet facilities available varied significantly between those with norovirus-positive compared to norovirus-negative diarrheal illnesses, with pit latrines with slab bases the most common toilet facility among children with norovirus-positive episodes. Otherwise, there were no significant differences in the demographic or clinical features of norovirus-positive versus norovirus-negative diarrheal illnesses in those with available data in our cohort, including rotavirus vaccination status, duration of diarrhea, duration of fever, presence of blood in stool, vomiting, abdominal pain, fever, or rotavirus stool positivity (Table [1](#Tab1){ref-type="table"}). Similarly, there were no significant differences in the clinical features of norovirus infections compared to rotavirus infections (data not shown). Similarly, when the severity of illness was compared according to the detection of norovirus or rotavirus, no significant differences were observed (norovirus-positive/rotavirus negative: 10/13 (77%) mild, 3/13 (23%) moderate; rotavirus-positive/norovirus negative: 66/84 (79%) mild, 18/84 (21%) moderate, norovirus-positive/rotavirus-positive 6/6 (100%) mild; *p* = 0.065). Similarly, no differences were observed in illness severity among GI compared to GII norovirus infections (Table [2](#Tab2){ref-type="table"}).Table 2Severity score by norovirus genogroup\* in young Zambian children with norovirus-associated diarrheal illnessGenogroup I (*n* = 4)Genogroup II (*n* = 10)*p*-valueSeverity score1.000  \< =10 (mild)3 (75.0)8 (80.0) 11--14 (moderate)1 (25.0)2 (20.0)  \> =15 (severe)0 (0.0)0 (0.0)\*Includes data only for subjects in whom severity score was calculable (*n* = 19) and genogroup was available (*n* = 14; one subject excluded due to co-infection with GI and GII)

Discussion {#Sec14}
==========

We present the first report to our knowledge of the rate of norovirus infections among young children with diarrheal illness in Zambia using data obtained from a systematic surveillance study. The period prevalence of norovirus in these facilities was 11.5%, compared to 41% rotavirus period prevalence in this partially vaccinated population \[[@CR7]\]. Diarrheal illness due to NoV is common among young children in this setting, and may become more important as rotavirus vaccine uptake increases. The clinical characteristics of norovirus positive and negative illnesses were not distinguishable. Several distinct norovirus genotypes were identified in this population, with GII represented in nearly three-quarters of the norovirus detections.

The recent finding that NoV replaced rotavirus as the leading etiology of childhood diarrhea after widespread rotavirus vaccine implementation in the United States \[[@CR4]\] has generated substantial interest in defining the burden of norovirus disease in other regions. Several studies have examined the prevalence of norovirus detection among children presenting with diarrheal infections in sub-Saharan Africa. In the multicenter Global Enteric Multicenter Study (GEMS), conducted from 2007 to 2011, norovirus did not contribute substantially to mortality in children \<5 years presenting to one of seven field sites in Asia or Africa with moderate-to-severe diarrhea \[[@CR16]\]. In contrast, a multi-site birth cohort study of children utilizing prospective community surveillance conducted at several sites in South America, Asia, and Africa from 2009 to 2012 (Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development Project; MAL-ED), found that NoV GII infections were associated with the highest or near-highest attributable burden of diarrheal illness in the first and second years of life \[[@CR17]\]. Further, they found that 89% of children experienced at least one norovirus infection before 24 months, with similar disease severity to other enteropathogens \[[@CR18]\]. The difference in these findings may be related to study design; while the GEMS study was designed as a case--control study and primarily recruited from health centers, the prospective birth cohort MAL-ED study captured household disease. Recent studies evaluating the prevalence of diarrheal pathogens among children with diarrhea in sub-Saharan Africa have reported NoV prevalence ranging from 9 to 25% among subjects with diarrhea, with typically 75 to 95% of symptomatic NoV detections associated with detection of NoV G.II \[[@CR18]--[@CR28]\]. In the studies that also enrolled asymptomatic controls, the prevalence of NoV in stool specimens obtained from asymptomatic subjects ranged from 3.9 to 31% and sometimes exceeded the prevalence in symptomatic subjects. However, cycle threshold values as surrogates for viral loads were useful in identifying clinically relevant NoV detections \[[@CR21], [@CR22]\]. Additionally, inter-study comparisons are limited by the use of different NoV detection methods as well as different definitions of cases and controls, reducing the generalizability of the two studies to other settings.

Our study has several important limitations. First, our surveillance was impaired by uneven collection of data. Clinical data were collected but were not systematically recorded in the first five months of the study, representing 37% of the total stool samples that were tested for norovirus. Study data collection forms were changed in November 2012; thus, the clinical features of illnesses prior to this transition are not captured. Additionally, stool samples were not collected from a substantial proportion of enrolled subjects (521/2027; 26%). The sample size of our study and the large number of missing stool samples are both important limitations, which may impact the generalizability of our results. In addition, our use of a convenience sample, rather than a random sample, may have introduced selection bias, as well as over- or under-representation of some months. Including both clinical and health care utilization parameters as enrollment criteria, some of which were subjective, may have resulted in misclassification bias. Additionally, we did not obtain samples from healthy control children without diarrhea for norovirus testing to inform the clinical significance of our results. Finally, the use of more restrictive primers may have underestimated the overall burden of norovirus in diarrheal illness in this population, and more sensitive, multiplex PCR tests may be applied to these samples in the future.

A significant difference identified in our study between norovirus-positive and norovirus-negative illnesses was latrine type. As oral-fecal contamination is an important route of transmission for norovirus and other enteric viruses, sanitation that allows appropriate disposal of feces may be an important intervention. However, given the wide variation of latrines prevailing in developing countries, it remains to be demonstrated whether improved latrines, such as those connected to a sewer line or with a lined sub-structure, may be associated with lower risk of infections such as norovirus.

Conclusions {#Sec15}
===========

Norovirus was detected frequently from children \< 5 years of age presenting with diarrhea in our sample derived from a health facility-based surveillance study. Longitudinal data will be needed to study changes in the relative importance of norovirus as a cause of clinically important diarrhea after widespread rotavirus vaccination implementation. Our findings and others may inform future strategies to prevent the morbidity and mortality associated with pediatric diarrheal infections.

Additional file {#Sec16}
===============

Additional file 1: Figure S1.Phylogenetic analysis of a 280-bp region of the partial RNA dependent-RNA polymerase region in norovirus detections (1A: Genogroup I; 1B: Genogroup II). (PDF 79 kb)
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